Replies to post #4404 on Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

[Amatuer17]

One major correction

The units sold is not number of tablets but no of packets and each packet seems to be 30 tablets

So the peak sale was 4 million packets or 120 million tablets per year (just in US)

[scottsmith]

That is all true but ktov is more than celebrex. It will not have the bb label. It will say ktov reduces risk. So I think the reality is something in btw.

[whan7]

The numbers do not make sense. The units in the graph are not tablets. If you are saying that at its peak Celebrex revenue per year was (4million tablets x $10per tablet) = $40 million $. That is way off. Celebrex had peak sales in the billions. The link you posted shows a quarterly revenue of $530mil. That's $2b in a year.

Say you're right and Kit-302 is similar to generics and only can make 1/10th that. (Should be somewhere in between actually.) So $200m+ rev per year. Ktovs MC is like $30mil right now.

These are more realistic unless I am totally missing something. A buyout should begin at near $400mil valuation IMO.